Thus, therapeutic interventions addressing IL-17 cytokines and IL-17-signaling are a potential strategy to reduce pulmonary inflammation in chronic lung diseases, especially when combined with additional therapeutic approaches, such as immunotherapy in lung cancer. This evidence concerns the gene IL17A and chronic lung disease.